摘要
目的评价细菌溶解产物(泛福舒)联合糖皮质激素以及白三烯调节剂治疗小儿哮喘的临床疗效。方法将83例轻度、中度的小儿支气管哮喘患者,随机分为对照组(n=42)和实验组(n=41)。对照组给予常用药物吸入型糖皮质激素(布地奈德)治疗,实验组在对照组的基础上再给予口服泛福舒以及白三烯调节剂治疗。比较两组患儿外周血中T细胞亚群和嗜酸性粒细胞水平、日夜间哮喘症状评分以及总有效控制率。结果治疗8周后,同对照组相比,实验组患儿外周血中CD+4、CD+4/CD+8细胞明显地升高(P<0.05),而CD+8水平显著下降(P<0.05),外周血中嗜酸性粒细胞显著降低(P<0.05)。两组患儿治疗前后日夜间哮喘症状评分均显著下降(P<0.05),且实验组下降幅度显著高于对照组(P<0.05),对照组与实验组临床疗效总有效率分别为76.19%和95.12%,差异具有统计学意义(P<0.05)。结论细菌溶解产物(泛福舒)联合糖皮质激素以及白三烯调节剂治疗小儿哮喘,能够明显改善患儿的免疫功能。
Objective To investigate the clinical efficacy of Broncho-Vaxom combined with corticosteroids and lcukotriene modifier in the treatment of children with asthma. Methods 78 children with mild, moderate bron- chial asthma were randomly divided into the control group (rt =42) and the experiment group (n =41 ). The control group received conventional drugs inhaled corticosteroid ( budesonide ) treatment, and the experiment group were treated with Broncho-Vaxom and leukotriene modifier on the basis of the control group. The data of T cell subsets and eosinophils level in peripheral blood, asthma symptom scores during daytime and night, and total effective control rate were compared between the two groups. Results 8 weeks after the treatment, the levels of CD4 and CD4+/CDs cells in peripheral blood increased more significantly in the experiment group than in the control group ( P 〈 0.05 ), but the level of CD8+ cells and eosinophils in peripheral blood decreased significantly ( P 〈 0. 05 ). The asthma symptom scores during daytime and night decreased significantly in the two groups ( P 〈 0. 05 ), and the decrease was more pronounced in the experiment group than in the control group ( P 〈 0. 05 ). The total clinical efficacy in the control group and the experiment group was 76. 19% and 95. 12% respectively ( P 〈 0. 05 ). Conclusion Broncho-Vaxom combined with corticosteroids and ]eukotriene modifier can significantly improve their immune function in the treatment of children with asthma.
出处
《临床肺科杂志》
2016年第4期694-697,共4页
Journal of Clinical Pulmonary Medicine